Big Pharma spent more than any other industry to lobby Congress and federal agencies this year, a Reuters analysis shows, but is still on course for a major defeat by failing to stop a bill that allows the government to negotiate prices on select drugs. Despite the pharmaceutical industry spending at least $142mn on lobbying efforts, the $430bn Inflation Reduction Act to change climate, health, and tax policies cleared its largest hurdle last week when Democratic lawmakers passed it in the Senate. The US House of Representatives was also expected to pass it yesterday, allowing President Joe Biden to sign it into law. Its enactment would represent a rare legislative defeat for the pharmaceut
Hence then, the article about us move to negotiate drug prices a rare defeat for big pharma was published today ( ) and is available onGulf Times ( Qatar ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( US move to negotiate drug prices a rare defeat for Big Pharma )